Melanotan II is a synthetic peptide that activates multiple melanocortin receptors simultaneously, producing skin tanning, sexual arousal, and appetite suppression — along with a reliable side-effect profile that includes nausea and spontaneous erections.
What it does
Melanotan II (MT-II) is a synthetic, cyclic version of alpha-melanocyte stimulating hormone (α-MSH), a naturally occurring signaling molecule. Unlike α-MSH, MT-II binds non-selectively to all five melanocortin receptors (MC1R through MC5R), which means it triggers several distinct biological pathways at once rather than one clean effect Stefano 2022.
At MC1R, MT-II activates melanocytes — the pigment-producing cells in skin — ramping up an enzyme called tyrosinase, which drives eumelanin (dark pigment) synthesis. The result is skin darkening. UV exposure accelerates this, but is not strictly required A 2024. At MC4R in the hypothalamic paraventricular nucleus, MT-II engages the brain's central sexual arousal pathway, independent of blood-flow mechanisms used by drugs like sildenafil Stefano 2022. This MC4R pathway also suppresses appetite and, via the area postrema (the brain's nausea center), causes nausea. MC3R activation modulates energy homeostasis Hailan 2024, and MC5R stimulation affects sebaceous (oil) glands in skin A 2024.
This non-selectivity is the central trade-off with MT-II: tanning, arousal, appetite suppression, and nausea all arrive together. PT-141 (bremelanotide), which later became an FDA-approved drug for female sexual dysfunction, was derived directly from MT-II research — developed specifically to isolate the MC4R sexual effects with less of the rest.
What the evidence shows
Skin tanning and pigmentation Moderate human evidence for pigmentation effect; one ongoing trial in vitiligo
MT-II reliably darkens skin by stimulating eumelanin synthesis through MC1R activation. This effect is well-documented in human users and supported by its mechanism A 2024. An ongoing registered trial (NCT07437560) is evaluating MT-II as an adjunct to narrowband UVB phototherapy for repigmentation in stable vitiligo, suggesting enough scientific interest to warrant formal study. The concern with this use case is that the same melanocyte-stimulating activity that darkens normal skin may also accelerate growth or change the appearance of existing moles, including atypical ones — which is why melanoma history and atypical nevi are absolute contraindications.
Sexual arousal / erectile function Small human trials with positive findings; mechanism well-established
MT-II's sexual effects were discovered incidentally during tanning research and are mediated through central MC4R activation in the hypothalamus — a vascular-independent pathway distinct from PDE5 inhibitors Stefano 2022. This mechanism directly led to the development of bremelanotide (PT-141), now FDA-approved for hypoactive sexual desire disorder in premenopausal women. Spontaneous erections are among the most consistently reported effects in user experience surveys Eimear 2021. The sexual effects appear in both men and women, though most formal human data comes from male populations in small trials.
Appetite suppression and weight management Strong animal evidence; limited direct human data
MC3R and MC4R activation both contribute to energy balance. Animal studies show that depletion of α-MSH signaling leads to insatiable appetite and significant weight gain Yang-Wen 2021, and direct melanocortin agonism in the nucleus accumbens decreases both appetite and food-seeking behavior L 2022. MC4R agonism is an established anti-obesity target in pharmacology Hailan 2024. In human self-reports, appetite suppression is a commonly noted effect Eimear 2021, but no controlled human trials have evaluated MT-II specifically for weight management.
Mood and stress modulation Rodent data only; no human trials
In male rat models of chronic unpredictable stress, MT-II showed antidepressant-like and antistress effects comparable to the peptide Semax S 2024. Melanocortin signaling in social contexts has also been shown to selectively activate the nucleus accumbens in an oxytocin-dependent manner, suggesting mood-related pathways L 2024. These findings are interesting but entirely preclinical — there is no human trial data supporting MT-II for mood or stress.
How it's used
In studies and self-reported protocols, doses range from 0.25 mg subcutaneous (subQ) injection daily during a loading phase up to 0.5–1 mg daily, then tapering to 2–3 times per week for maintenance. Lower starting doses (0.25 mg) are typically used to assess nausea tolerance before increasing. MT-II has a tissue half-life of approximately 33 hours, which supports less-than-daily dosing once pigmentation is established. Evening dosing is commonly reported to blunt nausea during sleep. MT-II is administered subcutaneously — typically in abdominal fat — and is not an oral compound.
Side effects and safety
The most consistent side effects are nausea and facial flushing, both dose-dependent and most pronounced at the start of use Eimear 2021. Spontaneous erections in men are common enough to be considered an expected pharmacological effect rather than a side effect at typical doses. Headache, appetite suppression, and fatigue are also frequently reported.
The most clinically significant concern is mole darkening and potential new nevi (mole) formation — both documented in user surveys Eimear 2021. Because MT-II broadly stimulates melanocyte activity, its use in anyone with a personal or family history of melanoma, atypical moles, or active skin malignancy is considered an absolute contraindication. Whether MT-II can cause melanoma de novo in otherwise low-risk individuals is unresolved; the theoretical risk exists but is unquantified. Rhabdomyolysis (breakdown of muscle tissue, potentially damaging the kidneys) has been reported rarely. Long-term safety data in humans is essentially absent — MT-II is not an approved drug, and systematic follow-up studies do not exist.
Bottom line
MT-II has a well-understood mechanism and reliably produces tanning and sexual arousal effects, with moderate human evidence and a predictable side-effect profile. The absence of long-term safety data and a credible — if unquantified — melanoma risk make it a poor choice for anyone with skin cancer risk factors. People seeking the sexual function effects specifically are generally better served by bremelanotide (PT-141), which was developed to deliver the MC4R benefits with fewer off-target effects.